Idorsia Ltd (IDIA.SW)
CHF 1.3
(2.45%)
CHF 1.3
(2.45%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -254.55 Million CHF | 33.08% |
| 2022 | -783.08 Million CHF | -32.99% |
| 2021 | -588.83 Million CHF | -39.99% |
| 2020 | -420.63 Million CHF | 9.1% |
| 2019 | -457.34 Million CHF | -31.64% |
| 2018 | -349.81 Million CHF | -16306.22% |
| 2017 | 2.16 Million CHF | 100.71% |
| 2016 | -305.33 Million CHF | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q3 | -92 Million CHF | 21.63% |
| 2024 Q1 | -90.77 Million CHF | 136.33% |
| 2024 Q2 | -92.83 Million CHF | -355.31% |
| 2023 Q3 | 237.42 Million CHF | 229.98% |
| 2023 FY | - CHF | 33.08% |
| 2023 Q1 | -201.81 Million CHF | -12.47% |
| 2023 Q2 | -182.65 Million CHF | 9.49% |
| 2023 Q4 | -110.65 Million CHF | -146.61% |
| 2022 Q3 | -194.08 Million CHF | 8.25% |
| 2022 FY | - CHF | -32.99% |
| 2022 Q4 | -179.44 Million CHF | 7.54% |
| 2022 Q2 | -211.52 Million CHF | -13.1% |
| 2022 Q1 | -187.01 Million CHF | 18.78% |
| 2021 FY | - CHF | -39.99% |
| 2021 Q4 | -230.25 Million CHF | -78.31% |
| 2021 Q3 | -129.13 Million CHF | 2.26% |
| 2021 Q2 | -132.12 Million CHF | -35.75% |
| 2021 Q1 | -97.32 Million CHF | 27.61% |
| 2020 FY | - CHF | 9.1% |
| 2020 Q3 | -112.36 Million CHF | -80.9% |
| 2020 Q1 | -111.69 Million CHF | 16.87% |
| 2020 Q2 | -62.11 Million CHF | 44.39% |
| 2020 Q4 | -134.45 Million CHF | -19.66% |
| 2019 Q2 | -115.65 Million CHF | -1.55% |
| 2019 Q1 | -113.89 Million CHF | -20.8% |
| 2019 FY | - CHF | -31.64% |
| 2019 Q4 | -134.36 Million CHF | -35.98% |
| 2019 Q3 | -98.81 Million CHF | 14.57% |
| 2018 Q3 | -111.2 Million CHF | -49.01% |
| 2018 Q1 | -71.39 Million CHF | -192.52% |
| 2018 FY | - CHF | -16306.22% |
| 2018 Q4 | -94.28 Million CHF | 15.21% |
| 2018 Q2 | -74.62 Million CHF | -4.53% |
| 2017 FY | - CHF | 100.71% |
| 2017 Q1 | -106.83 Million CHF | 0.0% |
| 2017 Q2 | 100.92 Million CHF | 194.47% |
| 2017 Q4 | 77.16 Million CHF | 219.7% |
| 2017 Q3 | -64.46 Million CHF | -163.88% |
| 2016 FY | - CHF | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Addex Therapeutics Ltd | -10.22 Million CHF | -2388.605% |
| BB Biotech AG | -201.25 Million CHF | -26.481% |
| Basilea Pharmaceutica AG | 29.49 Million CHF | 963.031% |
| Evolva Holding SA | -98.35 Million CHF | -158.802% |
| Kuros Biosciences AG | -10.4 Million CHF | -2345.489% |
| Molecular Partners AG | -59.51 Million CHF | -327.709% |
| Relief Therapeutics Holding AG | -108.2 Million CHF | -135.255% |
| Santhera Pharmaceuticals Holding AG | 79.17 Million CHF | 421.508% |